Radiation and Immune Therapy-ARC2019
This session will help radiation oncology professionals remain current in the field of immunotherapies and radiation combined with immunotherapies. Attendees need to be able to recognize and identify side effect profiles and presenting symptoms of toxicities from immunotherapies which are used clinically. Novel tumor vaccines that use conventional and exploratory cancer therapies will be discussed.
This activity is available from May 08, 2019, through 11:59 p.m. Eastern time on May 07, 2022.
This activity was originally recorded at ASTRO’s 2019 Annual Refresher Meeting, April 5-7, 2019 in New Orleans, LA.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, radiation physicists, nurses, radiation therapists, and radiation dosimetrists.
- Describe the mechanisms and potential utility of radiation-mediated in situ vaccines.
- Discuss the importance of clinical trials in studying immune-oncology therapies and how such trials might be designed.
Chandon Guha, MD is employed by Albert Einstein College of Medicine, Montefiore Medical Center, receives compensation/remuneration/funding from Celldex Therapeutics, Focused Ultrasound Foundation, Johnson and Johnson, National Institute of Health, Varian, holds ownership or investment interests in Rubicon Therapeutics, and holds a leadership position at NRG/RTOG.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.